

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Kevin Jeffrey Barnham, et al.

Serial No.: 10/530,137

Filed: October 3, 2005

For: NEUROLOGICALLY-ACTIVE
COMPOUNDS

Mailstop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450



Examiner: Unassigned

Art Unit: 1624

Docket: 18803

Dated: January 24, 2007

INFORMATION DISCLOSURE STATEMENT

Sir:


In accordance with 37 C.F.R §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. U.S. Patent No. 6,369,058 B1, April 9, 2002 to Hussain, et al.;
2. U.S. Patent No. 5,902,810 A, May 11, 1999 to Pfleiderer, et al.;
3. U.S. 2002/0025944 A1, February 28, 2002 to Bush, et al.;
4. Chemical Abstract 45:48030 (& Yakugaku Zasshi (1945), 65, 69)
See Chem Abs RN410543-30-5;

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mailstop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 24, 2007.

Dated: January 24, 2007


Xiaochun Zhu


5. Chemical Abstract 111:194704 (& Tetrahedron Letters (1989), 30 (12), 1529-39);
6. Chemical Abstract 24:53157 (& Journal of the American Chemical Society, 1930, 52, 3974.7);
7. Chemical Abstract 48:46261 (& Journal of the Chemical Society, Abstracts, 1952, 5985-5993);
8. EP 0 290 819 B1, November 17, 1988 to Bioresearch S.p.A.;
9. WO 02/085908 A1, February 29, 2002 to Bush, et al.;
10. WO 03/010146 A1, February 6, 2003 to Neuro3D;
11. WO 03/016309 A1, February 27, 2003 to Merck & Co., Inc.;
12. WO 95/12417 A1, May 11, 1995 to ACEA Pharmaceuticals Inc., et al.;
13. WO 94/24379 A1, September 14, 1995 to Cancer Research Campaign Technology Limited;
14. WO 98/06403, February 19, 1998 to Gerolymatos, S.A.;
15. WO 02/50065 A2, June 27, 2002 to Vertex Pharmaceuticals Inc.;
16. WO 98/47969A1, October 29, 1998 to University of Pittsburgh;
17. WO 96/22990 A1, August 1, 1996, The State of Oregon;
18. Koshimuro K. et al. "The Role of 6R-tetrahydrobiopterin in the nervous system", Progress in Neurobiology 61 (2000), 415-438.

The references were cited in an International Search Report dated January 6, 2004.

Applicants are submitting copies of Reference Nos. 4-18, as required by 37 C.F.R. 1.98 (a)(2)(i) and (ii), together with a copy of the Search Report. The relevance of the above-identified references has been described in the Search Report.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,



Xiaochun Zhu

Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza - Ste. 300
Garden City, New York 11530
(516) 742-4343
XZ:bk

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY DOCKET NO. 18803	APPLICATION NO. 10/530,137
	APPLICANT(S) Kevin Jeffrey Barnham, et al.	
	FILING DATE 10/3/2005	GROUP ART UNIT 1624

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,369,058 B1	4/9/2002	Hussein, et al.			
	5,902,810 A	5/11/99	Pfleiderer, et al.			

U.S. PATENT APPLICATION PUBLICATIONS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	2002/0025944 A1	2/20/02	Bush, et al.			

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP 0 290 819 B1	11/17/88	EPO			✓	
	WO 02/085908 A1	2/20/02	PCT			✓	
	WO 03/010146 A1	2/2/03	PCT			✓	
	WO 03/016309 A1	2/27/03	PCT			✓	
	WO 95/12417 A1	5/11/95	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Chemical Abstract 45:48030 (& Yakugaku Zasshi (1945), 65, 69 ; Chem Abs RN410543-30-5
		Chemical Abstract 111:194704 (& Tetrahedron Letters (1989), 30 (12), 1529-39)

EXAMINER /Jeffrey Murray/	DATE CONSIDERED 08/06/2008
------------------------------	-------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>	ATTY DOCKET NO. 18803	APPLICATION NO. 10/530,137
	Kevin Jeffrey Barnham, et al.	
	FILING 10/3/2005	GROUP ART 1624

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

U.S. PATENT APPLICATION PUBLICATIONS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 94/24379 A1	9/14/95	PCT			✓	
	WO 98/06403	2/19/98	PCT			✓	
	WO 02/50065	6/27/02	PCT			✓	
	WO 98/47969 A1	10/29/88	PCT			✓	
	WO 96/22990 A1	8/1/96	PCT			✓	

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
		Chemical Abstract 24:53157 (& Journal of the American Chemical Society, 1930, 52, 3974.7)
		Chemical Abstract 48:46261 (& Journal of the Chemical Society, Abstracts, 1952, 5985-5993).




EXAMINER	/Jeffrey Murray/	DATE CONSIDERED	08/06/2008
----------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. 18803	
In Re Application Of: Kevin Jeffrey Barnham, et al.						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/530,137	10/3/2005	Unassigned	23389	1624	4715	
Title: NEUROLOGICALLY ACTIVE COMPOUNDS						
<p>Address to:</p> <p>Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450</p> <p>37 CFR 1.97(b)</p> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <p style="text-align: center;">37 CFR 1.97(c)</p> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <p style="margin-left: 40px;"><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p style="text-align: center;">OR</p> <p style="margin-left: 40px;"><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p>						

P10A/REV06

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. 18803	
In Re Application of: Kevin Jeffrey Barnham, et al.						
						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/530,137	10/3/2005	Unassigned	23389	1624	4715	
Title: NEUROLOGICALLY ACTIVE COMPOUNDS						
Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))						
<input type="checkbox"/> A check in the amount of _____ is attached. <input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. <u>19-1013/SSMP</u> as described below.						
<input type="checkbox"/> Charge the amount of _____ <input checked="" type="checkbox"/> Credit any overpayment. <input checked="" type="checkbox"/> Charge any additional fee required.						
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.						
Certificate of Transmission by Facsimile*				Certificate of Mailing by First Class Mail		
I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa _____ (Date) _____ Signature _____ Typed or Printed Name of Person Signing Certificate				I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on January 24, 2007 _____ (Date)  Signature of Person Mailing Correspondence Xiaochun Zhu _____ Typed or Printed Name of Person Mailing Certificate		
*This certificate may only be used if paying by deposit account. <div style="display: flex; justify-content: space-between; align-items: flex-end;"> <div style="width: 40%;">  Signature </div> <div style="width: 55%;"> Dated: January 24, 2007 </div> </div>						
Xiaochun Zhu Registration No. 56,311 Scully, Scott, Murphy & Presser, PC 400 Garden City Plaza, Suite 300 Garden City, New York 11530 (516) 742-4343						
cc: XZ:bk						

P10A/REV06

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./